JNJ/PTGX: JNJ2113: Oral dosing faces hurdles of new rival classes in psoriasis & Ulcerative Colitis

The injectable IL23 class has been successful in treating a wide variety of inflammatory conditions such as psoriasis and inflammatory bowel disease, with its favourable risk benefit, placing them early in treatment landscape leading: thus the search for oral alternatives with similar efficacy leads to JNJ2113, a first in class oral IL23 antagonist developed by JNJ and Protagonist, aiming to fill this void